Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saredutant in Major Depressive Disorder
NCT00250627Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2004
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of saredutant in major depressive disorder (MDD) (3 arms), sponsored by Sanofi. Primary endpoint: Hamilton Depression Rating Scale Total Score at Day 56. Started Dec 2004; status: completed.
02
Drugs
saredutant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00250627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250627.